InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: None

Monday, 10/02/2006 5:43:33 PM

Monday, October 02, 2006 5:43:33 PM

Post# of 19309
Overall, I’m neutral on the LFB deal.

Good news:

GTC will now have $57M in cash come January, plus or minus a couple of million This figure comes from summing GTC’s prior guidance for cash at year-end (paragraph 3 of #msg-12428542), LFB’s $25M equity purchase, and LFB’s $2.6M term loan. (The $57M figure excludes any cash that GTC might realize from the exercise of warrants issued in prior financings.)

Thus, if one defines cash rich as having more than $50M in cash on the balance sheet, GTC will be cash-rich for the first time in a very long time (perhaps ever). This will remove one of the biggest psychological hurdles for investors and it may allow the share price to finally move northward.

Bad news:

For giving up 20% of the company on a post-transaction basis, GTC is not getting as much as I would have expected. A transgenically produced rhFVIIa should be able to under-price NVO’s NovoSeven and it may well become a decent-selling product in due course, but we’re talking about a potential product launch circa 2013 (my estimate), and seven years is an eternity in this business.

Moreover, I do not especially like the kind of loose, open-ended collaboration that GTC and LFB inked, which allows each partner to decide on the fly the degree to which it will fund the program. GTC has had a less than stellar experience in this kind of collaboration with Fresenius on the albumin program, and I would have expected GTC to opt for a tighter, more focused deal with less potential for a future disagreement.

--
That’s my knee-jerk reaction to today’s announcement. I’ve been out of the office all day and am just catching up; will post more about the deal this evening after suitable reflection.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.